- Home
- MITQ vs SILO Comparison
MITQ vs SILO Comparison
Compare MITQ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- SILO
- Stock Information
- Founded
- MITQ N/A
- SILO 2010
- Country
- MITQ United States
- SILO United States
- Employees
- MITQ N/A
- SILO N/A
- Industry
- MITQ Telecommunications Equipment
- SILO Apparel
- Sector
- MITQ Telecommunications
- SILO Consumer Discretionary
- Exchange
- MITQ Nasdaq
- SILO Nasdaq
- Market Cap
- MITQ 8.0M
- SILO 8.8M
- IPO Year
- MITQ 2021
- SILO N/A
- Fundamental
- Price
- MITQ $0.73
- SILO $1.59
- Analyst Decision
- MITQ
- SILO
- Analyst Count
- MITQ 0
- SILO 0
- Target Price
- MITQ N/A
- SILO N/A
- AVG Volume (30 Days)
- MITQ 4.5M
- SILO 598.0K
- Earning Date
- MITQ 02-18-2025
- SILO 02-18-2025
- Dividend Yield
- MITQ N/A
- SILO N/A
- EPS Growth
- MITQ N/A
- SILO N/A
- EPS
- MITQ N/A
- SILO N/A
- Revenue
- MITQ $18,756,000.00
- SILO $72,102.00
- Revenue This Year
- MITQ N/A
- SILO $1.86
- Revenue Next Year
- MITQ N/A
- SILO N/A
- P/E Ratio
- MITQ N/A
- SILO N/A
- Revenue Growth
- MITQ N/A
- SILO N/A
- 52 Week Low
- MITQ $0.42
- SILO $0.77
- 52 Week High
- MITQ $1.55
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- MITQ 48.16
- SILO 52.57
- Support Level
- MITQ $0.68
- SILO $1.56
- Resistance Level
- MITQ $0.76
- SILO $1.89
- Average True Range (ATR)
- MITQ 0.05
- SILO 0.19
- MACD
- MITQ -0.01
- SILO -0.05
- Stochastic Oscillator
- MITQ 25.97
- SILO 27.12
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.